查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2128963

遺傳性血管性水腫治療市場：依藥物類別、治療方法、給藥途徑、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Hereditary Angioedema Therapeutics Market, By Drug Class, By Treatment Type, By Route of Administration, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 267 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025年遺傳性血管性水腫治療市值為34.906億美元，預計從2026年到2033年將以10.6%的複合年成長率成長。

遺傳性血管性水腫 (HAE) 治療市場包含用於預防或治療由遺傳性血管性水腫 (HAE) 引起的複發性水腫的藥物。 HAE 是一種罕見的遺傳性疾病，其特徵是激肽釋放酶-激肽系統失調。目前有多種療法可供選擇，包括 C1 酯酶抑制劑、緩激肽 B2 受體拮抗劑、激肽釋放酶抑制劑以及更新、更具特異性的生物製藥。這些藥物分為「按需治療」（在發作期間給藥）和「預防性治療」（減少發作頻率）。市場越來越關注標靶治療和便捷的給藥方式，包括皮下注射和口服給藥。

遺傳性血管性水腫治療市場—市場動態

人們越來越需要有效預防 HAE 發作並迅速治療它。

預防危及生命的急性發作和治療急性遺傳性血管性水腫 (HAE) 的臨床需求日益成長，是推動遺傳性血管性水腫 (HAE) 治療市場成長的關鍵因素。 HAE 可導致皮膚、胃腸道和上呼吸道反覆腫脹。喉部急性發作是一種潛在的危及生命的併發症。由於該疾病具有慢性復發性，患者除了按需治療外，可能還需要長期治療和預防。據估計，HAE 的發生率約為五萬分之一，顯然是一種需要特殊護理的罕見疾病。

此外，標靶特定通路藥物在治療領域也日益受到關注。 C1酯酶抑制劑用於補充或取代不足的C1-INH，而激肽釋放酶抑制劑和緩激肽受體拮抗劑則用於靶向引起腫脹的下游成分。居家給藥和口服給藥方式的日益普及，進一步加速了口服製劑、皮下製劑和預填充充式給藥裝置製劑的研發。

遺傳性血管性水腫治療市場—市場區隔分析：

全球遺傳性血管性水腫治療市場按藥物類別、治療類型、給藥途徑、最終用戶和地區進行細分。

從藥物類別來看，激肽釋放酶抑制劑預計將成為市場的主要組成部分，因為血漿激肽釋放酶被認為是與遺傳性血管性水腫（HAE）發炎相關的緩激肽路徑的關鍵成分。此類藥物包括用於治療HAE發作和預防的口服和注射藥物。 2025年7月，FDA批准了EKTERLY（cevetralstat），一種用於治療急性HAE發作的口服血漿激肽釋放酶抑制劑。該藥物的核准是基於KONFIDENT試驗的結果，該試驗在20個國家的66個研究中心納入了110名受試者。該藥物為口服片劑，在發作後立即服用，凸顯了按需治療中口服激肽釋放酶抑制劑的重要性。

預防性治療的重要性日益凸顯。這是因為患者和醫生越來越希望不僅能獲得緊急治療，還能永久降低發作頻率。例如，2025年6月，FDA批准了ANDEMBRY（加拉達西單抗）用於預防遺傳性血管性水腫（HAE）發作。該療法在首次給藥後，每月進行一次皮下注射。

遺傳性血管性水腫治療市場—區域分析

由於罕見疾病的專科服務、完善的保險報銷和治療保障、臨床試驗以及新療法快速的法規核准，北美遺傳性血管性水腫 (HAE) 治療市場已發展成為全球最發達的市場之一。 2025 年，包括 ANDEMBRY（6 月）、EKTERLY（7 月）和 DAWNZERA（8 月）在內的幾種重要的 HAE 治療藥物獲得了美國 FDA 的批准。這些核准的藥物為市場帶來了新的治療選擇，例如單株抗體預防性治療、按需口服治療和 RNA 標靶預防性治療。

歐洲地區也是一個重要的市場，因為該地區罕見疾病治療基礎設施完善，且患者能夠便捷地獲得罕見疾病免疫學和過敏學專家的診療服務。例如，CSL公司宣布其產品已獲得澳洲和英國的監管部門批准，歐盟委員會也於2025年2月11日批准了ANDEMBRY上市。這種每月一次的標靶因子XIIa的療法已獲准在歐洲用於預防遺傳性血管性水腫（HAE）。

目錄

第1章：遺傳性血管性水腫治療市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：遺傳性血管性水腫治療的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：遺傳性血管性水腫治療藥物的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：遺傳性血管性水腫治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：遺傳性血管性水腫治療藥物的市場狀況

  • 2025年遺傳性血管性水腫治療藥物市佔分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：遺傳性血管性水腫治療市場：依藥物類別分類

  • 概述
    • 基於細分市場的市場佔有率分析：按藥物類別分類
    • C1酯酶抑制劑
    • 血漿激肽釋放酶抑制劑
    • 緩激肽B2受體拮抗劑
    • 因子 XIIa 抑制劑
    • RNA標靶療法
    • 其他

第8章：遺傳性血管性水腫治療市場：依治療類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 按需治療
    • 預防性治療

第9章：遺傳性血管性水腫療法市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 靜脈
    • 皮下
    • 口服

第10章：遺傳性血管性水腫治療市場：依最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 醫院
    • 專科診所
    • 家庭醫療保健
    • 其他

第11章：遺傳性血管性水腫治療市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章：主要供應商分析：遺傳性血管性水腫治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Takeda Pharmaceutical Company Limited
    • CSL Behring
    • Pharming Group NV
    • BioCryst Pharmaceuticals, Inc.
    • Chiesi Group
    • Ionis Pharmaceuticals, Inc.
    • Pharvaris NV
    • Sanofi
    • Arrowhead Pharmaceuticals, Inc.
    • Intellia Therapeutics, Inc.
    • Grifols, SA
    • Octapharma AG
    • Swedish Orphan Biovitrum（Sobi）
    • Kedrion Biopharma Inc.
    • Adverum Biotechnologies, Inc.
    • Attune Pharmaceuticals, Inc.
    • BioMarin Pharmaceutical Inc.
    • Regeneron Pharmaceuticals, Inc.
    • ADARx Pharmaceuticals, Inc.
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7323

Hereditary Angioedema Therapeutics Market size was valued at US$ 3,490.6 Million in 2025, expanding at a CAGR of 10.6% from 2026 to 2033.

The Hereditary Angioedema (HAE) Therapeutics Market comprises drugs that prevent or cure recurring swellings from hereditary angioedema (HAE), which is a rare inherited condition marked by the dysregulation of the kallikrein-kinin system. There are different kinds of treatment that can be used including C1-esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors as well as other newer, more specific biological treatments. The drugs may be categorized as on-demand treatment, which is applied during an attack of the disease, or prophylactic, which decreases the frequency of attacks. The market is increasingly focusing on targeted treatment and convenient administration of the drug including subcutaneous and oral therapy.

Hereditary Angioedema Therapeutics Market- Market Dynamics

Rising Need for Effective Long-Term Prevention and Rapid Treatment of HAE Attacks

The increasing clinical need for preventing attacks that might become life-threatening and for treating HAE in acute conditions is the important reason for Hereditary Angioedema Therapeutics Market growth. The swelling of the skin, gastrointestinal tract, and upper respiratory passage may happen repeatedly in HAE. The complication that might become life-threatening is laryngeal attacks. The disease is chronic and recurrent, so patients might need chronic treatment and prevention as well as on-demand treatment. HAE is thought to affect about 1 in every 50,000 people, clearly a rare disease that needs additional care.

Pathway-specific medicines are also becoming the focus of the treatment environment. C1-esterase inhibitors are used to replace or replace a defective C1-INH, kallikrein inhibitors and bradykinin receptor antagonists are used to target downstream components that cause swelling. Increasingly frequent preference for home dosing and oral administration further drives development of oral and subcutaneous and prefilled-device formulations.

Hereditary Angioedema Therapeutics Market- Segmentation Analysis:

The Global Hereditary Angioedema Therapeutics Market is segmented on the basis of Drug Class, Treatment Type, Route of Administration, End User, and Region.

Drug Class shows that Kallikrein Inhibitors are expected to be a major contributor since plasma kallikrein is considered a major part of the bradykinin pathway associated with HAE inflammation. The category includes oral and injectable treatment for HAE attacks and prophylaxis. FDA has approved EKTERLY (sebetralstat), which is an oral plasma kallikrein inhibitor for acute HAE attacks in July 2025. The drug received its approval based on the results of the KONFIDENT study involving 110 participants across 66 sites in 20 countries. The treatment comes as a tablet to take orally when an attack is first noticed, thus highlighting the importance of oral kallikrein inhibition in on-demand treatment.

Prophylaxis Treatment is becoming more relevant because patients and physicians are increasingly looking for a permanent decrease in attack frequency, not just emergency treatment. In June 2025, for instance, FDA approved ANDEMBRY (garadacimab) specifically for the prevention of HAE attacks, a treatment that is administered subcutaneously once a month after a loading dose.

Hereditary Angioedema Therapeutics Market- Geographical Insights

The Hereditary Angioedema therapeutics market in North America is one of the most advanced regions as it has witnessed specialized services for rare diseases, robust reimbursement and treatment care, clinical trials, and quick regulatory acceptance of novel therapies. In 2025, several key HAE drugs were approved by the U.S. FDA, such as ANDEMBRY (June), EKTERLY (July), and DAWNZERA (August). These approvals brought additional treatment options to the market for monoclonal-antibody prophylaxis, oral on-demand therapy and RNA-targeted prophylaxis.

The European region is also a key market due to its well-developed treatment infrastructure for rare diseases and access to rare disease immunology and allergy specialists. For instance, CSL said it had secured regulatory approvals in Australia and UK, with the European Commission approving ANDEMBRY on February 11, 2025. European authorization was granted for use of a Factor XIIa-targeting once-monthly therapy for HAE prophylaxis.

Hereditary Angioedema Therapeutics Market- Competitive Landscape:

The Hereditary Angioedema Therapeutics Market features intense competition from plasma derived product manufacturers and biotech firms developing drugs for targeted kallikrein, bradykinin, Factor XIIa, and RNA therapeutics. Some of the major market players include CSL Behring, Takeda Pharmaceutical Company, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharming Group, Intellia Therapeutics, and CENTOGENE. The focus of the competition has been shifting to the number of attacks reduced, how quickly to respond, how long the interval between doses and how easy it is to administer at home.

Recent Developments:

In July 2026, Pharvaris announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for deucrictibant immediate-release capsules to treat a hereditary angioedema attack when needed. The application included favorable clinical results showing fast onset, long duration of response and a favourable safety profile. April 23, 2027 was the FDA's PDUFA action date.

In December 2025, GENESIS Pharma signed an exclusive partnership agreement with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema (HAE) in Central and Eastern Europe. GENESIS Pharma has agreed to be the exclusive distributor and commercialiser of donidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Poland, Romania, Slovakia and Slovenia.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Takeda Pharmaceutical Company Limited
  • CSL Behring
  • Pharming Group N.V.
  • BioCryst Pharmaceuticals, Inc.
  • Chiesi Group
  • Ionis Pharmaceuticals, Inc.
  • Pharvaris N.V.
  • Sanofi
  • Arrowhead Pharmaceuticals, Inc.
  • Intellia Therapeutics, Inc.
  • Grifols, S.A.
  • Octapharma AG
  • Swedish Orphan Biovitrum (Sobi)
  • Kedrion Biopharma Inc.
  • Adverum Biotechnologies, Inc.
  • Attune Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • Regeneron Pharmaceuticals, Inc.
  • ADARx Pharmaceuticals, Inc.
  • Others

GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

  • C1-Esterase Inhibitors
  • Plasma Kallikrein Inhibitors
  • Bradykinin B2 Receptor Antagonists
  • Factor XIIa Inhibitors
  • RNA-Targeted Therapies
  • Others

GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

  • On-Demand Treatment
  • Prophylaxis Treatment

GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Intravenous
  • Subcutaneous
  • Oral

GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Hereditary Angioedema Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
  • 2.2. Competitive Insights

3. Hereditary Angioedema Therapeutics Key Market Trends

  • 3.1. Hereditary Angioedema Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hereditary Angioedema Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hereditary Angioedema Therapeutics Market Opportunities
  • 3.4. Hereditary Angioedema Therapeutics Market Future Trends

4. Hereditary Angioedema Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hereditary Angioedema Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Hereditary Angioedema Therapeutics Market Landscape

  • 6.1. Hereditary Angioedema Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hereditary Angioedema Therapeutics Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
    • 7.1.2. C1-Esterase Inhibitors
    • 7.1.3. Plasma Kallikrein Inhibitors
    • 7.1.4. Bradykinin B2 Receptor Antagonists
    • 7.1.5. Factor XIIa Inhibitors
    • 7.1.6. RNA-Targeted Therapies
    • 7.1.7. Others

8. Hereditary Angioedema Therapeutics Market - By Treatment Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
    • 8.1.2. On-Demand Treatment
    • 8.1.3. Prophylaxis Treatment

9. Hereditary Angioedema Therapeutics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
    • 9.1.4. Oral

10. Hereditary Angioedema Therapeutics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Home Healthcare
    • 10.1.5. Others

11. Hereditary Angioedema Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Hereditary Angioedema Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Hereditary Angioedema Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Hereditary Angioedema Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Hereditary Angioedema Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Hereditary Angioedema Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Hereditary Angioedema Therapeutics Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Takeda Pharmaceutical Company Limited
    • 12.2.2. CSL Behring
    • 12.2.3. Pharming Group N.V.
    • 12.2.4. BioCryst Pharmaceuticals, Inc.
    • 12.2.5. Chiesi Group
    • 12.2.6. Ionis Pharmaceuticals, Inc.
    • 12.2.7. Pharvaris N.V.
    • 12.2.8. Sanofi
    • 12.2.9. Arrowhead Pharmaceuticals, Inc.
    • 12.2.10. Intellia Therapeutics, Inc.
    • 12.2.11. Grifols, S.A.
    • 12.2.12. Octapharma AG
    • 12.2.13. Swedish Orphan Biovitrum (Sobi)
    • 12.2.14. Kedrion Biopharma Inc.
    • 12.2.15. Adverum Biotechnologies, Inc.
    • 12.2.16. Attune Pharmaceuticals, Inc.
    • 12.2.17. BioMarin Pharmaceutical Inc.
    • 12.2.18. Regeneron Pharmaceuticals, Inc.
    • 12.2.19. ADARx Pharmaceuticals, Inc.
    • 12.2.20. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us